Genenta Science S.p.A (GNTA) Common Equity (2020 - 2025)
Genenta Science S.p.A (GNTA) posted Common Equity of $25.4 million for Q4 2025, up 85.4% sequentially from $13.7 million in Q2 2025, and up 90.4% YoY from $13.4 million in Q4 2024.
Genenta Science S.p.A (GNTA) Common Equity (2020 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Common Equity for 6 years, with the latest figure at $25.4 million in Q4 2025.
- Quarterly Common Equity rose 90.4% year-over-year to $25.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.4 million (up 90.4% YoY) and the FY2025 annual result came in at $25.4 million, up 90.4% from the prior year.
- Common Equity advanced to $25.4 million in Q4 2025 per GNTA's latest filing, from $13.7 million in the prior quarter.
- Over five years, Common Equity peaked at $44.5 million in Q4 2021 and troughed at $13.4 million in Q4 2024.
- A 5-year average of $26.1 million and a median of $25.4 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2024: Common Equity jumped 146.09% in 2021, then sank 39.26% in 2024.
- Over 5 years, Common Equity stood at $44.5 million in 2021, then fell by 28.54% to $31.8 million in 2022, then slumped by 30.8% to $22.0 million in 2023, then tumbled by 39.26% to $13.4 million in 2024, then jumped by 90.4% to $25.4 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $25.4 million, $13.7 million, and $13.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Genenta Science S.p.A | 23.36 Mn | -35.73 Mn | - | 25.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.42 Mn |
| Jun 30, 2025 | 13.71 Mn |
| Dec 31, 2024 | 13.35 Mn |
| Jun 30, 2024 | 18.11 Mn |
| Dec 31, 2023 | 21.98 Mn |
| Jun 30, 2023 | 27.01 Mn |
| Dec 31, 2022 | 31.77 Mn |
| Jun 30, 2022 | 39.47 Mn |
| Dec 31, 2021 | 44.46 Mn |
| Dec 31, 2020 | 18.06 Mn |